**LETTER TO JMG**

**DHCR7 nonsense mutations and characterisation of mRNA nonsense mediated decay in Smith-Lemli-Opitz syndrome**


Smith-Lemli-Opitz syndrome (SLOS) is the prototypical example of a multiple congenital anomaly mental retardation syndrome due to an inborn error of cholesterol biosynthesis. The SLOS clinical spectrum ranges from a very mild disorder that combines learning and behavioural problems with minor malformations to a severe multiple malformation syndrome that results in prenatal/neonatal death. In 1998, three groups independently identified mutations of DHCR7 in SLOS patients. DHCR7 was mapped to chromosome 11q12–13 and encodes an NADPH dependent reductase that reduces 7-dehydrocholesterol (7DHC) to cholesterol in the last step of cholesterol biosynthesis. Molecular studies have shown that the carrier frequency for the most common SLOS mutant allele, IVS8-1G→C, is approximately 1% in Caucasian populations. Due to the deficiency of DHCR7 activity, SLOS patients have elevated 7DHC and typically decreased cholesterol levels. Decreased cholesterol levels have been associated with birth defects due to impaired hedgehog signalling during development.

One third of mutations underlying human disorders result in premature termination codons (nonsense mutations), which often lead to rapid degradation of the mutant mRNA by the nonsense mediated decay (NMD) pathway. Although the molecular mechanisms underlying NMD are not fully understood, NMD can be suppressed by experimental manipulations that impair the efficiency of translation. Aminoglycoside antibiotics, which bind to ribosomes, can induce translational read through of nonsense codons and thus suppress NMD. Restoration of protein function by NMD suppression has been reported in a number of autosomal recessive disorders such as cystic fibrosis and Hurler syndrome.

Four nonsense mutations have previously been described in SLOS. These are E37X, Q149X, W151X, and Y217X. W151X represents about 6.4% of identified mutations in SLOS patients and by haplotype analysis appears to be a relatively old DHCR7 mutation that initially arose in Southern Poland. We now report a novel premature stop mutation, Q98X, and demonstrate that both Q98X and W151X undergo NMD. Because the W151X allele is relatively common, we investigated whether suppression of NMD has therapeutic potential. Although NMD can be suppressed for the W151X allele, we found no increased fractional cholesterol synthesis in response to aminoglycoside treatment. Under identical conditions, we did observe an increase in fractional cholesterol synthesis for both of these alleles. This result suggests that the W151X position encodes a critical residue that cannot be substituted.

### Key points

- A novel DHCR7 nonsense mutation, Q98X, was identified.
- The phenotypic characteristics of 10 patients with the more common nonsense allele, W151X, are presented. Null mutations such as W151X allow genotype-phenotype correlations to be made for the second allele. Genotype-phenotype correlations are reviewed for common DHCR7 mutations.
- mRNA nonsense mediated decay of both the Q98X and W151X alleles is demonstrated, and the therapeutic potential of suppression of nonsense mediated decay for both of these alleles was investigated.
- Suppression of nonsense mediated decay using G418 increased fractional cholesterol synthesis in the Q98X cell line. However, G418 suppression of nonsense mediated decay of the W151X allele did not increase fractional cholesterol synthesis. This result suggests that the W151X position encodes a critical residue that cannot be substituted.

### Mutation analysis

Depending on the available sample, different methods were used to obtain genomic DNA. In cases where patient material was not available, DHCR7 genotyping was performed on DNA obtained from parents. Genomic DNA was isolated from whole blood (EDTA), using a Gentra Systems (Minneapolis, MN, USA) DNA isolation kit. Genomic DNA was purified from newborn metabolic screening blood spots and skin fibroblasts as previously described. Common SLOS mutations (IVS8-1G→C, W151X, T93M, R404C, and V326L) were excluded as previously described. Coding regions were amplified from genomic DNA as previously described.

RNA was extracted using a Qiagen RNEasy Mini Kit (Qiagen, Valencia, CA, USA). To obtain DHCR7 cDNA, RT-PCR was performed using an Invitrogen Superscript One-Step RT-PCR with Platinum Taq kit (Invitrogen, Carlsbad, CA, USA). For RT-PCR the forward and reverse primers were

### Abbreviations

- 7DHC, 7-dehydrocholesterol
- DMEM, Dulbecco’s Modified Eagle’s Medium
- LPDS, lipoprotein deficient serum
- NMD, nonsense mediated decay
- SLOS, Smith-Lemli-Opitz syndrome

---

**METHODS**

**Patient population and phenotypic analysis**

This work was approved by the NICHD Institutional Review Board, and informed consent from guardians was obtained for skin biopsies or DNA analysis. Medical records and autopsy results were obtained with guardian consent. Cholesterol and 7DHC concentrations in plasma were determined by gas chromatography/mass spectrometry as previously described. Severity scores were calculated as previously described.

Depending on the available sample, different methods were used to obtain genomic DNA. In cases where patient material was not available, DHCR7 genotyping was performed on DNA obtained from parents. Genomic DNA was isolated from whole blood (EDTA), using a Gentra Systems (Minneapolis, MN, USA) DNA isolation kit. Genomic DNA was purified from newborn metabolic screening blood spots and skin fibroblasts as previously described. Common SLOS mutations (IVS8-1G→C, W151X, T93M, R404C, and V326L) were excluded as previously described. Coding regions were amplified from genomic DNA as previously described.

RNA was extracted using a Qiagen RNEasy Mini Kit (Qiagen, Valencia, CA, USA). To obtain DHCR7 cDNA, RT-PCR was performed using an Invitrogen Superscript One-Step RT-PCR with Platinum Taq kit (Invitrogen, Carlsbad, CA, USA). For RT-PCR the forward and reverse primers were
HSP1D (5'-AGGTGGCCGAGGACTTTAG-3') and HSP13 (5'-GCTGGGCTCTCCTGAGTTA-3'), respectively. Reverse transcription was performed at 50°C for 30 min followed by a 2 min denaturation at 94°C. PCR amplification conditions were 35 cycles of 94°C for 15 s, 60°C for 30 s, and 72°C for 90 s. The reaction was completed with a final extension period of 72°C for 10 min. Sequencing primers were as previously described and DNA sequencing was performed on a CEQ2000 (Beckman Coulter, Fullerton, CA, USA) per the manufacturer's protocol. The membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was probed with 32P using 9HSP4 (5'-primers HSP1 (5'-TCTAGATGGCGTCACCAATGAC-3', GCTGGGCTCTCTCCAGTTTA-3').

**Cell culture**

Skin fibroblasts were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco-BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gemini, Woodland, CA, USA), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Gibco-BRL) at 37°C with 5% CO2. For experiments testing aminoglycoside treatment, cells were plated to obtain approximately 70% confluence after 18 h of growth. For growth under cholesterol deficient conditions, cultures were grown in McCoy's 5A medium (Gibro-BRL) supplemented with 7.5% lipoprotein deficient serum (LPDS). Fibroblast cultures were treated with either G418 or gentamicin (Mediatech, Herndon, VA, USA) for 48 h.

**Northern blot analysis**

A 5 μg sample of total RNA was separated on a 1% agarose/ formaldehyde gel and transferred to a Hybond-N+ nylon membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The DHCR7 probe was generated by RT-PCR with primers HSP1 (5'-TCTAGATGGCGTCACCAATGAC-3', GCTGGGCTCTCTCCAGTTTA-3') and HSP4 (5'-CTGTGAAATCGACTCTTG-3') using DHCR7 cDNA as template." The probe was labelled with 32P using the Rediprobe II Random Prime Labeling System (Amersham Pharmacia Biotech). A human GADPH probe was used to control for variation in RNA loading. Quantification of band intensity was performed using a BioImaging Analyzer (Fuji Medical Systems, Stamford, CT, USA).

**Fractional cholesterol synthesis**

To determine if DHCR7 enzymatic activity was increased by aminoglycoside treatment, human skin fibroblasts were cultured in McCoy's 5A Medium supplemented with 25% deuterium oxide (Sigma, St Louis, MO, USA), 7.5% LPDS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin at 37°C with 5% CO2. Incubation times and aminoglycoside concentrations are given in figure legends. Fractional cholesterol synthesis was determined by combined gas chromatography/flame ionisation detection and gas chromatography/mass spectrometry for the analysis of deuterium labelled steroids.

**RESULTS**

**Clinical descriptions and genotypes**

**Patient 1**

This phenotypically female infant was born at 36 weeks gestational age to a 19 year old G1P1 Caucasian mother and a 16 year old Caucasian father. The mother was of Polish, English, and German heritage: the father's ethnic background was unknown. Prenatal ultrasound at 31 weeks revealed intrauterine growth retardation, limb anomalies, a large ventricular septal defect, and oligohydramnios. Aminoacentesis was performed and the fetal karyotype was 46,XY. The infant was delivered by caesarean section due to fetal distress and breech presentation. The infant was intubated soon after birth for respiratory failure. Physical examination revealed the following: growth parameters in the 25th centile for gestational age (birth weight 2190 g, length 43 cm, head circumference 31.5 cm), low-set ears, bilateral anterior polar cataracts, broad nasal bridge, anteverted nares, capillary haemangioma on the nose, micrognathia, cleft palate, broad alveolar ridges, shield-like chest, female external genitalia, and aetresic anus. Limb anomalies consisted of bilateral upper extremity ectrodactyly, postaxial polydactyly of both feet, syndactyly of the second and third toes, and bilateral calcaneal valgus. Echocardiogram revealed a large, ventricular septal defect with an overriding aorta and right ventricular hypertrophy consistent with either a variant of tetralogy of Fallot or double outlet right ventricle. Head ultrasound was normal. Abdominal ultrasound revealed an atypical appearance of the left kidney without a definite focal mass. In addition, the abdominal ultrasound showed probable intra-abdominal testicles located near the inguinal canals with no evidence of female reproductive organs. Lower extremity radiographs revealed normal femora, tibiae, and fibulae, but bilateral clubfoot abnormalities with hypoplastic hindfoot and phalanges. Upper extremity radiographs revealed normal humeri, symmetric mesomorphic shortening of the forearms bilaterally with relatively greater shortening of the ulna, and lateral dislocation of the radial heads. Both hands were abnormal; only three metacarpals were identified in each hand, and three digits with relatively normal appearing phalanges were present on each hand. Cholesterol level was 0.16 mmol/l and the 7DH level was 0.21 mmol/l. Clinical severity score was 67. The infant died on the 10th day of life. A postmortem examination was declined. DHCR7 genotype was c.452G→A/c.461C→G (W151X/T154R).

**Patient 2**

This male infant was born to a 30 year old G1P3SA1 mother following an uncomplicated pregnancy and delivery; fetal movements were felt at 20 weeks of gestation and were of normal intensity. There were no prenatal tests and no significant family history. The infant was delivered at 39 weeks of gestation by spontaneous vaginal vertex delivery. Birth weight was 2940 g (25th centile), head circumference was 33 cm (10th centile), and length was 49 cm (25th centile). The infant had no difficulty feeding, but presented with dehydration and vomiting at 10 days of age because of pyloric stenosis and underwent pyloroplasty. Clinical
diagnosis of SLOS was made at age 3 months. Karyotype was 46,XY. At 5 months of age plasma cholesterol was 1.24 mmol/l, 7DHC was 0.06 mmol/l, and 8DHC was 0.05 mmol/l. At age 4.5 years, he was moderately mentally retarded. The child was able to walk in spite of the extreme tactile sensitivity of his feet. His speech consisted of only babbling. He was not toilet trained. He was restless and had opisthokinesis, but was generally happy and had no self-injurious behaviour. His weight was 10.6 kg (–3.82 SD), height was 98 cm (–2 SD), and head circumference was 44 cm (–5.7 SD). He had unusual silvery blond hair. Facial features included bitemporal narrowing of the head with a prominent occiput and a prominent metopic suture, bilateral ptosis and epicanthal folds, high arched palate, thick irregular alveolar ridge, small tongue, and micrognathia. He had a haemangioma on the nasal tip. He had a microgenis with glandular epipadias and bilateral cryptochordism. He had proximally set thumbs, overlapping fingers, ulnar deviation of the hands, and 2–3 toe syndactyly. He was Polish. Severity score was 30. DHCR7 genotype was c.452G→A/c.1054C→T (W151X/R352W).

Patient 4
This male patient was born to an 18 year old G 2P1 mother who previously had a child who appeared to be affected with SLOS. This sibling died at 14 days of age with characteristic physical anomalies; however, the diagnosis was not confirmed by biochemical testing. The current pregnancy was not complicated; no prenatal testing was undertaken with the exception of sonographic evaluation at 28 weeks of gestation that detected multiple anomalies: ambiguous genitalia, short humeri, polydactyly of all extremities, and cerebral ventriculomegaly. The patient was born at 36 weeks of gestation by a spontaneous vaginal vertex delivery. His birth weight was 2600 g (25th centile), length was 51 cm (50th centile), and head circumference was 32 cm (25th centile). He required gastrostomy tube feeding with recurrent vomiting. On examination at age 9.5 months included craniofacial features at 9.5 months included bitemporal narrowing, prominent occiput, high forehead, and a large open fontanel. He had bilateral ptosis and epicanthal folds, cleft palate, thick irregular alveolar ridge, bifid uvula, small tongue and micrognathia, and excessive sublingual tissue, as well as a long and flat philtrum. His neck was short and thick. He had an atrial septal defect, and there was a low-set left kidney. Genital anomalies consisted of a microgenit with penoscrotal hypospadias and bilateral cryptorchidism. Dysmorphic limb findings included rhizometric shortening of all extremities, proximally set thumbs, overlapping fingers, bilateral single palmar creases, broad halluces, postaxial polydactyly of hands and feet, valgus deformities of the ankles, and Y shaped 2–3 toe syndactyly. He had agenesis of corpus callosum, generalised cortical atrophy, and was hypotonic. He was Polish. Clinical severity score was 30. Karyotype was 46,XY. DHCR7 genotype was c.470T→G/c.309S→A (W151X/G309S).

Patient 6
This female child was born to a 33 year old G3S4A1T1 mother following an uncomplicated pregnancy. Fetal movements were first perceived at 22 weeks, but were weak. She was delivered at 40 weeks of gestation by caesarean section because of maternal pneumothorax. Her birth weight was 3000 g (25th centile), length was 51 cm (50th centile), and head circumference was 32 cm (less than 3rd centile). This infant failed to thrive in the first year of life. Urethral narrowing was corrected surgically at age 14 months. Formal psychometric testing showed an IQ of 70. The child was described as always being very irritable. The diagnosis of SLOS was made clinically at 1.5 years of age and confirmed biochemically at age 6. On physical examination at age 15 her weight was 37.7 kg (–2.0 SD), height was 152.3 cm (10th centile), and head circumference was 50.5 cm (–3.3 SD). Craniofacial features included bitemporal narrowing, prominent occiput and long midface with lateral hypoplasia. She had bilateral ptosis, minimal epicanthal folds, anteverted nares, high arched palate, and mild micrognathia. She had a sacral dimple and minimal 2–3 toe syndactyly. She was Polish. Clinical severity score was 20. At age 11 years cholesterol was 2.07 mmol/l, 7DHC was 0.06 mmol/l, and 8DHC was 0.05 mmol/l. Karyotype was 46,XX. DHCR7 genotype was c.452G→A/c.925G→C (W151X/G309S).

Patient 7
This male teenager was born to a 26 year old primigravida woman following a pregnancy complicated by a flu-like illness at 6–7 weeks of gestation. Fetal movements were felt at 6 months, but perceived as weak. He was delivered at 38 weeks by spontaneous vaginal vertex delivery with no neonatal complications. Birth weight was 2000 g (–3.4 SD), length was 49 cm (40th centile), and head circumference was 31 cm (3rd centile). He required gastrostomy tube feeding because of swallowing difficulties and a poor suck until 12 months of age. A clinical diagnosis of SLOS was made at age 7 years and confirmed biochemically at age 10 years with a cholesterol level of 3.16 mmol/l, 7DHC level of 0.13 mmol/l, and 8DHC level of 0.09 mmol/l. He had severe behavioural problems with restlessness, a high pitched cry, irritability,
marked tactile defensiveness, and head banging. At the age of 11 years, he was severely developmentally delayed with no speech. On physical examination at age 14 years, he was wheelchair dependent. His weight was 27.3 kg (−2.5 SD), height was 144.5 cm (−2.13 SD), and his head circumference was 49 cm (−4.25 SD). He had very fair skin and unusual silver blond hair. He had lateral midface hypoplasia, shallow orbits, a high forehead, and his ears were very low set, posteriorly rotated and had prominent lobules. He had neither ptosis nor short palpebral fissures, but did have minimal epicanthal folds. He had a short nose with a bulbous nasal tip. His mouth was wide and the corners were down turned. He had micrognathia, irregularly spaced uneven teeth, and a high arched palate. He had a narrow thorax with wide set nipples, and his pelvis was narrow. Examination of the genitalia was notable for cryptorchidism, hypospadias, and micropenis. His second toes were curved over his third bilaterally, he had a proximally set thumb with ulnar deviation of all fingers, hyperextended fingers, and short second digits. He was unapproachable for a very limited physical examination; he demonstrated severe tactile defensiveness of mouth, face, and extremities. Severity score was 30. He was Polish. Karyotype was 46,XY and DHCR7 genotype was c.452G→A/c.976G→T (W151X/V326L).

Patient 8

This young adult was born to a 32 year old primagravida mother after 42 weeks of gestation by spontaneous vaginal vertex delivery following an uncomplicated pregnancy. His birth weight was 3400 g (40th centile), length was 56 cm (25th centile), and head circumference was 34 cm (25th centile). He had feeding difficulties in spite of a good suck and required numerous hospitalisations for feeding issues. He underwent a hypospadias repair at age 12 years. He had no behavioural problems and his growth was appropriate. A clinical diagnosis of SLOS was made at age 7 months and confirmed biochemically at 15 years. Plasma cholesterol was 3.42 mmol/l, 7DHC was 0.60 mmol/l, and 8DHC was 0.41 mmol/l. At age 19.5 years, his weight was 61 kg (20th centile), height was 167.1 cm (below the 3rd centile), and head circumference was 56.6 cm (75th centile). He had bilateral short and proximally set thumbs and clinodactyly of second and fifth fingers and there were very short and proximally set thumbs and abnormal palmar creases. He had partial 2–3 syndactyly with overlap of all toes. Clinical severity score was 40. He was Polish. His karyotype was 46,XY. DHCR7 genotype was c.452G→A/c.1054C→T (W151X/R352W).

Patient 10

This male patient was born to a 27 year old primagravida mother following a pregnancy complicated by placenta previa and cervical insufficiency treated with bed rest for 2 months. The infant was delivered at 36 weeks of gestation by spontaneous vaginal vertex delivery. His birth weight was 2500 g (25–30th centile) and length was 49 cm (75th centile). He was admitted to the NICU because of respiratory difficulties and he required ventilation. He had a cleft palate, patent ductus arteriosus and secundum atrial septal defect, and anal stenosis requiring a colostomy (biopsy was negative for colonic aganglionosis). He had hypertension of unknown etiology in the newborn period. He had severe feeding problems and required feeding supplementation with nasal gastric tube feeding. He underwent a patent ductus arteriosus ligation at 4 months of age. He had recurrent infections with pneumonia. Head sonogram showed bilateral grade IV intraventricular haemorrhages with hydrocephalus. He had incomplete bladder emptying on voiding cystourethrogram (VCUG). He was diagnosed with SLOS at 2 weeks of age. His plasma cholesterol was 0.73 mmol/l, 7DHC was 0.49 mmol/l, and 8DHC was 0.18 mmol/l. At age 3 years, his weight was 6.85 kg (−5.3 SD), length was 81 cm (−3.5 SD), and head circumference was 44 cm (−4 SD). He had very fair, unusual silver blond hair. There was a forehead haemangioma and severe photosensitivity. His forehead was narrow and high, he had shallow orbits with down slanting palpebral fissures, blepharophimosis, and epicanthal folds. He had a short bulbose nose with anteverted nares. He had a repaired cleft palate, micrognathia, microglossia with abnormal tongue lobation, excess sublingual tissue, and thick alveolar ridges. He had a long and deep philtrum. Limb anomalies included short thumbs, abnormal palmar creases, zigzag index fingers, ulnar deviation of the middle fingers, 2–3 toe syndactyly, rhizomelic shortening of the extremities, and valgus deformities of the ankles. Genital anomalies consisted of hypospadias, micropenis, bifid scrotum, and undescended testes. He had a history of severe tactile hypersensitivity of hands and feet and self-injurious behaviour and was aggressive. He had opisthotonosis and severely fragmented sleep. He was Polish. Severity score was 55. Karyotype was 46,XY and DHCR7 genotype was c.452G→A/c.976G→T (W151X/V326L).

Patient 11

The male child was the product of a 41 week gestation to a 32 year old G2P1 mother. Pregnancy was notable for decreased fetal activity. Birth weight was 3000 g (25th evoked potentials, and head and abdominal sonograms were all normal. On physical examination at age 3.1 years his weight was 11.25 kg (−2.5 SD), length was 92.3 cm (−0.9 SD), and head circumference was 46 cm (3rd centile). He had a high forehead, scaphocephaly with metopic ridging, and bitemporal narrowing. His palpebral fissures were down slanting with epicanthal folds and blepharophimosis. He had bilateral cataracts. His ears were moderately large and had large lobules. He had characteristic antverted nares. He had a cleft palate, microglossia, abnormal tongue lobation, excess sublingual tissue, thick alveolar ridges, and micrognathia. His philtrum was long and he had lateral hypoplasia of the midface. His neck was short with excessive nuchal folds. He had an atrial septal defect. He had bilateral inguinal hernias and bifid scrotum. His hand digits had clinodactyly of the second and fifth fingers and there were very short and proximally set thumbs and abnormal palmar creases. He had partial 2–3 syndactyly with overlap of all toes. Clinical severity score was 40. He was Polish. His karyotype was 46,XY. DHCR7 genotype was c.452G→A/c.1054C→T (W151X/R352W).
centile), length was 49 cm (25th centile), and head circumference was 33 cm (10th centile). The infant was noted to be hypotonic with calcaneovalgus deformity of the right foot. He was breast fed for the first 4 months, but was noted to have a poor suck. He had mild facial characteristics of SLOS, including microcephaly, frontal bossing, low-set ears, epicanthal folds, broad nasal bridge, short philtrum, and mild palatal hypertrophy. Bilateral 2–3 toe syndactyly was present. Growth was appropriate for the first 6 months of life but then fell to below the 5th centile. Developmentally, the infant sat with support at 6 months of age, crawled at age 11 months, and walked at age 21 months. Behaviourally, he bites others and rarely plays with toys. A biochemical diagnosis of SLOS was made at 2 years of age. Both the mother and father are of Northern European ancestry. Clinical severity score was 6.

Plasma cholesterol was 2.95 mmol/l, 7DHC level was 0.14 mmol/l, and 8DHC was 0.13 mmol/l. Fractional cholesterol synthesis was measured in IVS8-1G→R151X fibroblasts treated with G418 (data not shown). This later result is likely due to significant background expression of the R450L allele in the cell line from this mildly affected patient.

Because G418 suppresses NMD of both the W151X and Q98X alleles, we investigated whether DHCR7 enzymatic activity could be increased by treatment with G418. Fractional cholesterol synthesis was measured in IVS8-1G→C/W151X fibroblasts treated with gentamicin, and a quantifiable increase in expression of DHCR7 mRNA was not detected in Q98X/R450L fibroblasts treated with G418 (data not shown). This later result is likely due to significant background expression of the R450L allele in the cell line from this mildly affected patient.

Figure 1
DHCR7 c.292C→T (Q98X) mutation. (A) A novel C to T transition resulting in the nonsense mutation Q98X was detected by sequencing at position c.292 of DHCR7 from patient 11. This mutation creates a BfaI restriction site produced by the c.292C→T mutation. PCR amplification of control DNA gives rise to a single 300 bp band, whereas DNA from the heterozygous patient gives rise to the control 300 bp band and a 230 bp band specific to the c.292C→T allele. A 70 bp band that also results from BfaI digestion of the mutant allele is not shown.

Figure 2
Q98X and W151X transcripts undergo NMD. RNA was isolated from untreated (left panels) or G418 treated (right panels) skin fibroblasts. For both the Q98X (top panels) and W151X (bottom panels) cell lines, sequencing of RT-PCR products derived from untreated cells appeared to be homozygous for the wild type sequence (arrows). However, after treatment with G418, sequencing of RT-PCR products showed that these cell lines were heterozygous for the Q98X and W151X mutant alleles (arrows). These data demonstrate that RNA transcripts from these two mutant alleles undergo NMD and that NMD can be suppressed by G418 treatment. Note that the antisense sequence is shown for the W151X allele.

Characterisation of NMD and aminoglycoside suppression of NMD for the Q98X and W151X mutations
Suppression of NMD by aminoglycosides was studied in three SLOS fibroblast cell lines with premature stop codons W151X/T93M,21 W151X/IVS8-1G→C (patient 1), and Q98X/R450L (patient 11). Sequencing of cDNA derived from fibroblasts treated with G418 demonstrated two alleles, whereas only one allele was observed in cDNA from untreated fibroblasts (fig 2). This effect was observed with both G418 (10–1000 μg/ml) and gentamicin (10–500 μg/ml, data not shown). Since RT-PCR amplification of cDNA was not quantitative, we used northern blot analysis to evaluate DHCR7 expression in IVS8-1G→C/W151X fibroblasts treated with 0, 10, 25, or 50 μg/ml of G418 (fig 3A). DHCR7 expression increased almost twofold between untreated and treated cells (0.047 ± 0.081, 0.098, and 0.107 photo stimulated luminescent units/mm² for 0 v 10, 25, and 50 μg/ml of G418, respectively). A significant increase in expression was not detected in IVS8-1G→C/W151X fibroblasts treated with gentamicin, and a quantifiable increase in expression of DHCR7 mRNA was not detected in Q98X/R450L fibroblasts treated with G418 (data not shown). This later result is likely due to significant background expression of the R450L allele in the cell line from this mildly affected patient.

Because G418 suppresses NMD of both the W151X and Q98X alleles, we investigated whether DHCR7 enzymatic activity could be increased by treatment with G418. Fractional cholesterol synthesis was measured in IVS8-1G→C/W151X fibroblasts treated with G418 (data not shown). This later result is likely due to significant background expression of the R450L allele in the cell line from this mildly affected patient.

Because G418 suppresses NMD of both the W151X and Q98X alleles, we investigated whether DHCR7 enzymatic activity could be increased by treatment with G418. Fractional cholesterol synthesis was measured in IVS8-1G→C/W151X fibroblasts treated with G418 (data not shown). This later result is likely due to significant background expression of the R450L allele in the cell line from this mildly affected patient.

Because G418 suppresses NMD of both the W151X and Q98X alleles, we investigated whether DHCR7 enzymatic activity could be increased by treatment with G418. Fractional cholesterol synthesis was measured in IVS8-1G→C/W151X fibroblasts treated with G418 (data not shown). This later result is likely due to significant background expression of the R450L allele in the cell line from this mildly affected patient.
fractional cholesterol synthesis in the IVS8-1G→C/W151X cell line could be attributed to the W151X allele. Under these culture conditions, significant toxicity was observed in cultures treated with 25 and 50 µg/ml of G418. At 10 µg/ml of G418 we were not able to detect deuterium labelled (newly synthesised) cholesterol in either IVS8-1G→C/IVS8-1G→C (data not shown) or IVS8-1G→C/W151X (fig 3B) cell lines. Experimental conditions were used under which we are able to detect 12.95 pmol of cholesterol-D6 diluted into 518 pmol of cholesterol. For the Q98X/R450 cell line, significant residual activity is present in untreated cells due to the R450L allele; however, we were able to detect a significant increase (SD) in fractional cholesterol synthesis from 0.28 (0.02) to 0.37 (0.04) (p<0.01) when these cells were treated with 10 µg/ml of G418 (fig 3B).

**Phenotypic severity and genotype**

Establishing a genotype-phenotype correlation for SLOS has been confounded by the large number of mutant alleles and the fact that most patients are compound heterozygotes. The W151X allele, like the more common splice acceptor mutation, IVS8-1G→C, is a null allele. Thus, one would predict that phenotypic variability due to DHCR7 genotype would be related to the second allele, and because of this, clinical characterisation of patients with W151X alleles is of interest. Figure 4 presents the genotype and clinical severity of a series of patients with the more common DHCR7 mutant alleles found in association with either IVS8-1G→C or W151X. This figure is a compilation of data of the W151X patients presented above, unpublished data, and previously reported cases. There is a series of patients with the genotype who had severity scores less than 50. One IVS8-1G→C/IVS8-1G→C patient with a clinical severity score of 30 died at 30 days of life, and another infant with a severity score of 45 was severely affected with alobar holoprosencephaly, ambiguous genitalia, polydactyly, and respiratory distress, and died at 8 days of age. Although most patients with a T93M/null (IVS8-1G→C or W151X) genotype have a mild to classical phenotypic presentation, as previously reported, a distinct subset of patients has a more severe presentation (p<0.001). Clinical severity scores for patients with V326L/null and R404C/null genotypes range from classical to severe. In contrast, clinical severity for the R352W/null genotype ranges from mild to classical. Except for the lack of W151X/R404C patients, no significant differences between the W151X and IVS8-1G→C alleles were observed.

**DISCUSSION**

SLOS is a multiple malformation/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Unlike many human malformation syndromes but similar to inborn errors of metabolism, postnatal correction of the underlying biochemical defect may have beneficial therapeutic effects. Currently, dietary cholesterol supplementation is being used in attempts to treat individuals with SLOS; however, efficacy is limited by the number of factors including inability of dietary cholesterol to cross the blood-brain barrier.

Establishing a genotype-phenotype correlation for SLOS has been confounded by the fact that over 90 different DHCR7 mutations have been identified, and most patients are compound heterozygotes. In this manuscript, we have presented the phenotypic description of 10 patients with the W151X allele and a single patient with a novel Q98X allele. Because nonsense alleles, like the common IVS8-1G→C allele, are null alleles, description of these patients is important since any observed genotype-phenotype correlations would be due to the second allele. Figure 4 presents the correlation between clinical severity and a series of mutant alleles found in association with either an IVS8-1G→C or W151X allele. Although this information will be of general use in genetic counselling, this series expands and confirms our previous observation that other factors in addition to genotype significantly influence clinical severity scores. These factors could involve maternal factors or other genes involved in cholesterol synthesis/homeostasis or cholesterol metabolism to steroids or oxysterols. Recently, Witsch-Baumgartner et al have reported that maternal apoE genotype is significantly correlated with phenotypic severity. Although limb malformations are typical of SLOS, ectrodactyly is not commonly observed. Ectrodactyly has been reported previously in three cases of SLOS, however, patient 2 is the first SLOS patient for whom the diagnosis was both biochemically and molecularly confirmed.

Since the W151X allele is found in approximately 6.4% of SLOS patients, suppression of NMD is a potential therapeutic approach that could be considered in this subset of SLOS.

**Figure 3** Suppression of Q98X and W151X NMD by G418. (A) Northern blot analysis of DHCR7 expression in control (+/−) and IVS8-1G→C/W151X skin fibroblasts treated with the indicated dose of G418. DHCR7 expression increased in the IVS8-1G→C/W151X cell line in response to treatment with G418. The same membrane was probed using a GADPH probe to establish equivalent RNA loading. (B) Fractional cholesterol synthesis is significantly increased in the G418/ R450L cell line after treatment with 10 µg/ml of G418. Fractional cholesterol synthesis was below our limit of detection for both the untreated and treated W151X/IVS8-1G→C cultures. **p<0.01.
patients. In this manuscript, we demonstrate that both the common \textit{DHCR7\textsuperscript{W151X}} and the newly identified \textit{DHCR7\textsuperscript{IVS8-1G\rightarrowC}} alleles undergo NMD. Although aminoglycoside antibiotics are unlikely to be used therapeutically, they serve as a model system to demonstrate that suppression of NMD may have therapeutic benefit. Future development of less toxic drugs that suppress NMD would be of value in the treatment of many genetic disorders. We thus tested the ability of aminoglycoside antibiotics to suppress NMD in SLOS fibroblasts. We were able to demonstrate a significant increase of fractional cholesterol synthesis in the Q98X/R450L fibroblast line treated with 10 \( \mu \text{g/ml} \) of G418. The high basal level of DHCR7 activity in this cell line is presumably due to the R450L allele that has residual enzymatic function. Given the allele frequency, we were most interested in determining if increased DHCR7 activity could be demonstrated for the W151X allele. For these experiments we used an IVS8-1G\rightarrowC/W151X fibroblast line since the IVS8-1G\rightarrowC allele is a null allele. Although NMD of the W151X allele could be suppressed, we were unable to detect any significant increase in fractional cholesterol synthesis in the IVS8-1G\rightarrowC/W151X cell line treated with 10 \( \mu \text{g/ml} \) of G418. For the determination of fractional cholesterol synthesis, use of higher G418 concentrations was precluded by toxicity. Thus, although NMD of the W151X transcript can be suppressed, active DHCR7 protein does not appear to be produced. This suggests that the W151 amino acid of DHCR7 is a critical residue that cannot be substituted. Little structural data is available for DHCR7. However, W151 is predicted to be in a transmembrane domain by several models.\textsuperscript{11,15,17,18} Numerous other mutations have been reported in this predicted transmembrane domain. Thus, our conclusion that W151 encodes a critical residue is consistent with the idea that this region of the protein is critical for enzymatic function.

**DISCLAIMER**

The opinions or assertions contained herein are the private views of the authors (NRD and SWL) and are not to be construed as official or as reflecting the views of the Department of the Army, Department of the Navy, or the Department of Defense.

**ACKNOWLEDGEMENTS**

We would like to thank the parents and patients for their willingness to participate in this research study.

**Authors’ affiliations**

L S Correa-Cerro, C A Wassif, P A Krakowiak, D Cazomo, F D Porter, Unit on Molecular Dysmorphology, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA

J S Waye, M J M Nowaczyk, Department of Pathology and Molecular Medicine and Pediatrics, McMaster University, Hamilton, ON, Canada

N R Dobson, Department of Pediatrics, National Naval Medical Center, Bethesda, MD, USA

S W Levin, Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA

G Anadioti, Legacy Children’s Hospital, Pediatric Development and Rehabilitation, Portland, OR, USA

R D Steiner, Department of Pediatrics and Molecular and Medical Genetics, Child Development Rehabilitation Center, Doernbecher Children’s Hospital, Oregon Health & Science University, Portland, OR, USA

M Krajewska-Walasek, Department of Medical Genetics, The Children’s Memorial Health Institute, Warsaw, Poland

LCC is supported by a Fogarty Center Fellowship at the National Institutes of Health.

Competing interests: none declared

Correspondence to: Forbes D Porter, Heritable Disorders Branch, NICHD, NIH, DHHS, 10 Center Dr., Bethesda, MD 20892, USA; fdporter@mail.nih.gov

Received 12 May 2004

Revised version received 16 June 2004

**REFERENCES**


11. Clancy JP, Babek Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lynere R, Sarcher EJ, Bedwell DM. Evidence that...


